Critical Review: Urogen Pharma (NASDAQ:URGN) vs. Gilead Sciences (NASDAQ:GILD)

Urogen Pharma (NASDAQ:URGN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Urogen Pharma and Gilead Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$140.49 million	10.22	-$153.49 million	($2.75)	-10.71
Gilead Sciences	$29.44 billion	5.64	$8.51 billion	$7.34	18.22

Gilead Sciences has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Urogen Pharma has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Urogen Pharma and Gilead Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1	1	7	1	2.80
Gilead Sciences	0	4	25	0	2.86

Urogen Pharma currently has a consensus price target of $36.67, indicating a potential upside of 24.46%. Gilead Sciences has a consensus price target of $156.93, indicating a potential upside of 17.35%. Given Urogen Pharma’s higher probable upside, equities research analysts plainly believe Urogen Pharma is more favorable than Gilead Sciences.

Profitability

This table compares Urogen Pharma and Gilead Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Gilead Sciences	30.99%	48.19%	18.28%

Institutional & Insider Ownership

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Gilead Sciences beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.